Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03404297
Other study ID # 1710769547
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2018
Est. completion date December 31, 2019

Study information

Verified date September 2023
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The efficacy of locally sourced compression therapy in the management of chronic leg ulcers and Kaposi Sarcoma in western Kenya will be studied in a rural setting


Description:

Compression therapy is a well-established cornerstone therapy and part of routine clinical care for chronic leg ulcers from venous disease and lymphedema, including Kaposi sarcoma (KS)-associated lymphedema. Chronic leg ulcers, from trauma or chronic venous disease, and lymphedema have a significant impact on quality of life, driven by pain, foul odor, and restricted mobility. The provision of compression therapy in resource-limited settings, as in western Kenya and other regions of East Africa, is a major challenge. In western Kenya, locally available elastic stockings are priced at 10-15 USD (1000-1500 kshs) per pair. Pre-packaged brand name kits are not locally available or affordable for patients, as imported kits costs 7-20 USD (700-2000 kshs) per package. However, materials used routinely in wound care, namely elastic crepe, gauze, and zinc oxide, are readily available and affordable for patients. Supplies required to dress one affected leg for a week cost 2 USD (200 kshs). The use of locally-sourced routine wound care supplies for compression therapy is poised to have significant impact on reducing morbidity, social stigma, and economic loss associated with chronic leg ulcers and Kaposi sarcoma-associated lymphedema. Demonstration of its feasibility and efficacy in treating chronic leg ulcers and Kaposi sarcoma-associated lymphedema in western Kenya could have far-reaching implications for the treatment of these prevalent conditions across East Africa and sub-Saharan Africa. This project will utilize a 1) retrospective study design to evaluate the efficacy of compression therapy for the treatment of chronic leg ulcer patients seen at Turbo Health Center, one of the Academic Model for Providing Access to Healthcare (AMPATH) sites and 2) randomized controlled trial to evaluate the efficacy of compression therapy in the management of Kaposi sarcoma leg lymphedema patients seen at AMPATH/MTRH oncology clinics. If the outcomes of this project support the use of locally-sourced compression therapy in the treatment of chronic leg ulcers and Kaposi sarcoma-associated lymphedema, future studies for chronic leg ulcers will focus on scaling up use of locally-sourced compression therapy at other AMPATH clinics and exploring feasibility of community-based care. Future studies for Kaposi sarcoma lymphedema will focus on exploring feasibility of community or home-based lymphedema care.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Retrospective Chronic Leg Ulcer Arm Investigation Inclusion Criteria: - Older than 18 years of age - Received paste bandage compression therapy as part of routine wound care - Presence of venous ulcer for more than 6 weeks. Venous ulcer defined as a wound of the lower extremity in an individual with adequate lower extremity arterial flow located in the gaiter region of the leg (between the knee and ankle) with clinical signs of venous disease (edema, varicose veins) (19) OR - Presence of trauma-related ulcer for more than 6 weeks Exclusion Criteria: - Patients with peripheral arterial disease as documented via documented history or peripheral vascular physical examination. (20) - Patients diagnosed with diabetic foot ulcers - Patients diagnosed with ulcers from inflammatory conditions (pyoderma gangrenosum, vasculitis, rheumatoid arthritis, and other connective tissue diseases/autoimmune diseases) - Concomitant diagnosis of decompensated heart failure, acute phase dermatitis (at the time of the study), acute phase deep vein thrombosis Prospective Kaposi Sarcoma Investigation Inclusion Criteria: - Older than 18 years of age - Diagnosis of biopsy-proven Kaposi sarcoma with associated leg lymphedema - Leg lymphedema consistent with Campisi Clinical Stage 1B, 2, 3, 4 (Table 4). At these stages, lymphedema is clinically evident and not yet permanently fibrotic, sclerotic, or indurated with verrucous change. - HIV positive - On highly active anti-retroviral therapy - About to initiate a course of chemotherapy - Willingness to participate for the entire study duration, ranging from at least 14 weeks and up to 24 weeks, depending on randomization. - Provision of written Informed Consent Exclusion Criteria - HIV negative - Leg lymphedema consistent with Campisi Clinical Stage 1A or 5 (Table 4). At these stages, lymphatic dysfunction is not yet clinically evident (Stage 1A) or lymphedema has become permanently fibrotic, sclerotic, or indurated with verrucous change (Stage 5). - History of another cancer diagnosis - Concomitant peripheral arterial disease as documented via history or peripheral vascular physical examination - Concomitant diagnosis of decompensated heart failure, acute phase dermatitis (at the time of the study), rheumatoid arthritis, acute phase deep vein thrombosis - Diagnosis of medical conditions that may also lead to lower extremity lymphedema, including: congestive heart failure, filiariasis, previous vein stripping or peripheral vascular surgery - Current use of medications known to cause edema, (i.e. calcium channel blockers, systemic corticosteroids) - Pregnant

Study Design


Intervention

Other:
Locally sourced compression therapy
The dressing is made up of a zinc oxide impregnated compression wrapping

Locations

Country Name City State
Kenya Chulaimbo District Hospital Chulaimbo Nyanza
Kenya Moi Teaching and Referral Hospital Eldoret Uasin Gishu

Sponsors (6)

Lead Sponsor Collaborator
Indiana University Indiana Clinical and Translational Sciences Institute, Moi Teaching and Referral Hospital, Moi Univeristy, Purdue University, University of California, San Francisco

Country where clinical trial is conducted

Kenya, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete Resolution of ulcers (Chronic Leg Ulcer Evaluation) Proportion of completely healed ulcers at 12 weeks. The unit is number of patients with an ulcer, not number of ulcers. 3 years
Primary Change in Lower Extremity Lymphedema Index (LELI) for KS The Lower Extremity Lymphedema Index (LELI) is calculated by taking the sum of the squares of the circumference in 5 areas of a lower extremity and dividing it by the BMI. The LEL indices are significantly correlated with clinical stages and can be used as a severity scale. The LELI will compared at numerous time points throughout the study with the change in week 0 and week 14 being compared between the two arms. 3 years
Secondary Time elapsed between start of wound care and complete healing of wound (Chronic Leg Ulcer Evaluation) This will be assessed for the observational assessment of chronic leg ulcers 3 years
Secondary Pain and itch assessment using the Numerical Rating Scale (Chronic Leg Ulcer Evaluation) Changes in the Numerical Rating Scale will be Evaluated over the period of evaluation. This marker has been previously validated in the Kenyan setting we work in. 3 years
Secondary Ability to work (Chronic Leg Ulcer Evaluation) The time to improvement that facilitates work will be evaluated over the course of the observational assessment 3 years
Secondary Ability to perform household tasks (Chronic Leg Ulcer Evaluation) The time to improvement that facilitates completion of household duties will be evaluated over the course of the observational assessment 3 years
Secondary Lymphedema Quality-of-Life measure (LYMQOL) for Kaposi Sarcoma The Lymphedema Quality-of-Life measure (LYMQOL) has separate tools for assessing arm lymphedema and leg lymphedema. This will be compared across the two arms of the study 3 years
Secondary Change in EORTC in Kaposi Sarcoma The change in the EORTC QLQ C30 (overall health quality of life in cancer patients) will be used to compare changes from Week 0 to Week 14 between immediate intervention and delayed arm. The EORTC QLQ-C30 is a questionnaire developed by the European Organization for Research and Treatment of Cancer to assess the quality of life of cancer patients 3 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06445166 - Propranolol for the Treatment of Kaposi Sarcoma in Adults Phase 2
Recruiting NCT04941274 - Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma Phase 1/Phase 2
Completed NCT03160183 - Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
Recruiting NCT03993106 - A Study of sEphB4-HSA in Kaposi Sarcoma Phase 2
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Completed NCT00395278 - Development of Serologic Assays for Human Herpes Virus-8
Recruiting NCT02408861 - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Completed NCT03296553 - Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. Phase 2
Recruiting NCT04305691 - Trial of Ixazomib for Kaposi Sarcoma Phase 2
Completed NCT03316274 - Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma Early Phase 1
Recruiting NCT05859074 - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Phase 1
Terminated NCT04893018 - NT-I7 for Kaposi Sarcoma in Patients With or Without HIV Phase 1
Recruiting NCT06375122 - Natural History Study of Kaposi Sarcoma
Recruiting NCT05663502 - Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Recruiting NCT05329792 - L19IL2/L19TNF in Skin Cancer Patients Phase 2
Not yet recruiting NCT05411237 - Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma Phase 3
Completed NCT03050788 - Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma N/A
Terminated NCT01412515 - A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma Phase 2
Not yet recruiting NCT06004011 - AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) N/A
Withdrawn NCT02229981 - Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma Phase 1/Phase 2